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DAILY UNM GLOBAL HEALTH COVID-19 BRIEFING 
May 22, 2020 
Executive Summary 
 
NM Highlights: 12 positive cases at NMSU. Short-term rentals restrictions. Dine-in reopening. 
 
US Highlights: Models to forecast COVID-19 deaths. Places of worship reopening. Contact tracing at University 
of Alabama. 
International Highlights: More deaths among poor. Mortality data in Italy. High death toll in Brazil. Global 
vaccines fall behind. Italy cases drop. Vaccines to go through India. 
Epidemiology Highlights: Children not pandemic drivers.  
Healthcare Policy Recommendations: Burnout of HCWs. NYC surgeons’ response. Foggy glasses tips. 
Practice Guidelines: Recommendations are provided on surgical strategies during COVID-19, management of 
hypertension, anesthesia practice, avoiding drug-induced cardiovascular impairments, arrhythmia 
management, elective surgery reboot, nutritional management, stroke care, neurointerventional surgery, 
blood management. 
Testing: Unregulated tests identified. Interpreting test results. 
Drugs, Vaccines, Therapies, Clinical Trials:  Vaccine trials results. Vaccine moves to trials. Monoclonal antibody 
identified. Hydroxychloroquine no benefit. Adjuvant corticosteroid therapy. Old drugs may benefit. Vaccines 
inducing antibodies. 
Other Science: Mortality and CKD/liver disease. Transmission in pregnancy. Pathophysiology insights. 
Readmission characteristics. Sodium and severity. Simulated sunlight disinfects. 
 
All of our past briefings are maintained in a UNM library repository here. 
Our continuously curated practice guidelines in the context of COVID-19 can be found here. 
Our continuously curated therapeutic evidence is maintained here. 
You may submit content for future briefings here. 
NM Highlights 
 12 individuals at New Mexico State University tested positive for COVID-19 
New Mexico State University announced Thursday morning that 12 individuals connected with the university's main campus 
in Las Cruces and Doña Ana Community College have tested positive for COVID-19. All 12 individuals were asymptomatic. The 
university did not specify whether any of the individuals were students, staff or otherwise connected with the campus. 
 Short-term rentals hit hard by governor’s restrictions 
Since NM's shutdown, a flood of cancellations hit NM's vacation rentals in popular destinations like Santa Fe. For a short 
   
 
   
 
period from April to May, short-term rental owners could only provide housing to out-of-state health care workers staying in 
NM. Last week, the governor's announcement stated that short-term vacation rentals are limited to guests to NM residents 
only. With slow reopening, hotels can open while vacation rentals are not allowed to do so. Owners of such lodgings 
expressed feelings of discrimination. 
 NM Restaurant Association relieved with governor’s announcement of dine-in reopening June 1 
The NM Restaurant Association represents about 3,500 restaurants statewide. At least 210 permanently closed due to 
pandemic. The governor announced reopening of dine-in restaurants on June 1 giving restaurants to prepare the facilities for 
business again. 
 NM reports 8 more COVID-19 deaths and 153 additional cases on May 22 
As of today (5/22), the total positive cases and total deaths in the state are 6,625 and 302, respectively. The state has 
performed 158,383 tests, there are 206 individuals currently hospitalized for COVID-19, and 2,149 COVID-19 cases have 
recovered. NMDOH portal featuring epidemiologic breakdown of cases. NMDOH portal featuring epidemiologic breakdown 
of cases. 
US Highlights 
 CDC is monitoring 15+ different models to forecast possible COVID19 deaths in the US 
The national ensemble forecast suggests that the rate of increase in cumulative deaths is likely to slow but still exceed 
110,000 by June 13. States with low numbers of deaths reported to date are unlikely to see a rapid rise in the coming weeks, 
while states with high numbers of deaths reported to date are likely to see increases at varying rates.  
 Trump calls on states to immediately reopen places of worship 
Trump said governors should allow the houses of worship to re-open "right now for this weekend," and threatened that if 
they don't, "I will override the governors," he said, adding that "In America, we need more prayer, not less." Dr. Deborah Birx, 
White House coronavirus task force coordinator, said faith leaders considering reopening should be in touch with their local 
health departments to properly advise their congregants.  
 University of Alabama to require online health checks for those returning to campuses 
The University of Alabama system will allow students and staff to return to campus in the coming months but will require 
they submit online health checks every 3 days. Students and staff are also encouraged to utilize a contact tracing app, which 
notifies people who were near users reporting as virus-positive.  
International Highlights 
 Coronavirus mortality rate among poor is five times higher than among wealthy in Spanish region 
Reuters: A study on Catalonia’s coronavirus cases and fatalities against age and income showed: Age 45-64, male mortality 
rate was 100 per 100,000 in the poorest group versus 20 in the wealthiest group. Female mortality rate was 50 versus 10. 
Age 65-79, male mortality rate was 500 versus 250 and female mortality rate was 300 versus 100. Age 79+, male mortality 
rate was 2,830 versus 1,910 and among women it was 1,360 versus 1,090. 
 Mortality increase directly and indirectly caused by the COVID-19 epidemic in Italy 
Data from 4433 municipalities providing mortality reports until April 15th, 2020 were included for a total of 34.5 million 
residents from all Italian regions. Data were analyzed by region, sex and age, and compared to expected from 2015-2019.  
77,339 deaths were observed between March and April, in contrast to the 50,822.6 expected. The rate ratio was 1.11 before 
age 60 and 1.55 afterwards. Both sexes were affected. An excess of 45,033 deaths in the study period, while the number of 
COVID-19 deaths was 21,046.  Possible causes included both the undetected cases and the disruption of the Health Service 
organization.  
 Brazil coronavirus deaths surpass 20,000 
Aljazeera: The health ministry said on Thursday the 1,188 deaths recorded over the previous 24-hour period pushed the 
overall tally to 20,047. Brazil, the epicenter of the pandemic in Latin America, has now recorded more than 310,000 
   
 
   
 
confirmed case. 
 80M children in 68 countries at risk for infectious disease from lack of immunizations 
Reuters: Travel restrictions and delivery delays have restricted regular immunization scheduling to third world countries. 
Experts are concerned that the restrictions could impact a COVID vaccine reaching millions if a vaccine is ever developed.  
 Daily coronavirus deaths dips but new cases steady in Italy 
Reuters: Italy recorded 130 new deaths from the COVID-19 epidemic on Friday against 156 the day before, while the daily 
tally of new cases rose marginally to 652 from 642 on Thursday.  
 Indian company could manufacture COVID-19 vaccine 
Reuters: Serum Institute of India expects most vaccines will pass through their company. 
Epidemiology Highlights  
 Children are unlikely to be the main drivers of the COVID-19 pandemic 
A systematic review studied 700 scientific papers and letters and 47 full texts. Children accounted for a small fraction of 
COVID-19 cases and mostly had social contacts with peers or parents, rather than older people at risk of severe disease. Data 
on viral loads were scarce but indicated that children may have lower levels than adults, partly because they often have 
fewer symptoms, and this should decrease the transmission risk. Household transmission studies showed that children were 
rarely the index case and case studies suggested that children with COVID-19 seldom caused outbreaks.  Children are unlikely 
to be the main drivers of the pandemic. Opening up schools and kindergartens is unlikely to impact COVID-19 mortality rates 
in older people. 
Healthcare Policy Recommendations 
 Burnout of health care professionals: A global survey 
MedRx preprint: Survey of 2707 health care professionals from 60 countries found that burnout is prevalent at higher than 
previously reported rates and is related to high workload, job stress, and time pressure, and limited organizational support. 
Burnout could be mitigated by actions from healthcare institutions and other governmental and non-governmental 
stakeholders aimed at potentially modifiable factors, including providing additional training, organizational support, support 
for family, PPE, and mental health resources.  
 NYC acute care surgeons' response to the COVID-19 Pandemic 
Acute care surgeons at NYC hospital describe their strategies to achieve COVID-19 -related system-wide coordination, as well 
as institution- and service-specific reorganization. They focus on maximizing surge capacity, surgery-specific changes, and 
communication. 
 Tips to avoid foggy glasses when wearing a face mask 
Here are a few tips to help prevent glasses from fogging when wearing a face mask: Improve the fit of your mask, tape your 
mask, pull your mask up, use a commercial anti-fog wipe or spray.  
Practice Guidelines 
 Surgical strategies during the COVID-19 crisis: The Salzburg Concept 
A specialized "COVID Surgery Service (CSS)” was created in Austria, exclusively dealing with the COVID patients, comprised of 
6 surgeons as part of a newly established COVID-clinic. CSS provides a practical schematic algorithm for surgery strategy in 
infected/suspected COVID-19 patients.  
 Managing hypertension during COVID-19 pandemic 
The evidence summary on COVID-19 and hypertension is provided as well as practical management recommendations. For 
newly diagnosed hypertensive patients initiate calcium channel blockers as first-line therapy in all new patients, irrespective 
of ethnicity or age. The initiation of ACEi or ARBS requires repeat blood tests to ensure renal function and potassium levels 
   
 
   
 
remain stable, which might not be readily available. Once health-care systems have less demand towards the end of the year, 
consider switching to an appropriate ACEi or ARB. If patients are already on ACEi or ARB, there are currently insufficient data 
to suggest cessation of this. Remind patients of ‘sick-day rules’, and if they are unable to drink sufficiently and have diarrhea 
or vomiting or a persistently low blood pressure, then their ACEi or ARBs medications should be stopped whilst they recover 
to reduce the risk of acute kidney injury. All hypertensive patients are encouraged to procure upper-arm home blood 
pressure monitors and to do self-monitoring. This would allow for titration of medication through telemedicine clinics. 
Patients should have enough of antihypertensive medications for at least two weeks, as there may be delays in procuring 
repeat prescriptions. 
 Update for anesthetists on COVID-19 management 
An international group of researchers including from Oxford UK, provides the updated recommendations for anesthetists in 
the question-answer format. 
 Cardiovascular manifestations and their treatment during COVID-19 pandemic 
COVID-19 might directly cause cardiovascular injuries such as pericarditis, myocarditis, myocardial infarction, heart failure, 
arrhythmias or thromboembolic events, which urge cardiologists to be involved in the frontline to practice. A review is 
provided on cardiovascular system to assist clinical cardiologists to better understand and manage COVID-19. 
 COVID-19 Management and Arrhythmia 
There is an increased baseline arrhythmia risk in COVID-19 patients which increases further due to infection. The paper 
highlights a key role of hERG (or “Kv11.1”) potassium channels in drug-induced arrhythmia risk, in particular, QT interval 
prolongation. A list of medications is provided which could be used in the management of COVID-19 which are also 
associated with risk of QT prolongation (Propofol, Sevoflurane, macrolides, fluoroquinolones, Fluconazole, Pentamidine, 
Lopinavir/ritonavir, Favipiravir, anti-emetics Domperidone, Levomepromazine, Ondansetron, anti-arrhythmics Amiodarone, 
Flecainide, Ibutilide, Procainamide, Quinidine, Sotalol, antipsychotics Haloperidol, Quetiapine, Risperidone, Antimalarials such 
as Chloroquine, Hydroxychloroquine or Mefloquine). 
 Practical tips for a safe, successful and sustainable reboot of elective surgery 
7 practical tips are proposed, to be considered in stepwise progression, for healthcare systems looking to reboot their 
elective surgeries: 1) Know where you are on the epidemic curve; 2) Ensure access to reliable COVID-19 screening; 3) 
Understand hospital resources; 4) Ensure appropriate case selection and prioritization; 5) Optimize the patient’s post-
discharge planning; 6) Start small, stay current and be adaptable; 7) Be prepared for roadblocks ahead. 
 Nutritional management of COVID-19 patients in a rehabilitation unit 
Collaboration between the Rehabilitation Unit of the San Raffaele Scientific Institute and the dietetics service created an 
interdisciplinary and integrated management of the nutritional status of COVID-19 patients, based on the latest scientific 
data. Here the authors report their three-step nutritional protocol: 1) nutritional assessment and malnutrition screening; 2) 
setting the nutritional treatment; 3) continuous monitoring. 
 Impact of the COVID-19 on stroke care and potential solutions 
A survey of leaders from 280 stroke centers showed that capacity for stroke care was reduced in the majority of the 
hospitals. Most of the stroke centers stopped or reduced public stroke education. Hospital admissions related to stroke 
dropped by approximately 40%; thrombolysis and thrombectomy cases dropped by approximately 25%. Recommendations 
based on the data are provided. Stroke awareness education activities should be enhanced. Establishing a fast-track COVID-
19 screening process for patients with potential stroke is highly desirable. A rapid laboratory test for the virus should be 
prioritized for patients with stroke, and the test should be part of the existing stroke fast-track pathway. The initiation of 
stroke therapy should not be hindered by the COVID-19 screening. Resource management should be established as quickly as 
possible. A campaign to encourage appropriate hospital evaluation for emergent, treatable, time-sensitive diseases such as 
stroke and myocardial infarction should be initiated at a national level. 
 Chinese guidelines on prevention and control of COVID-19 during neurointerventional surgery 
Chinese Federation of Interventional and Therapeutic Neuroradiology (CFITN) and the International Society for 
Neurovascular Disease (ISNVD) compiled an expert consensus on fighting against the COVID-19, including infection 
   
 
   
 
prevention and control procedures in the outpatient/inpatient/catheterization lab settings, medical stuff self-protection, 
operating room requirements, management of suspected or confirmed COVID-19 cases, and treatment of emergency stroke 
patients. 
 Patient blood management during COVID-19 pandemic 
A meta-analysis revealed that the implementation of Patient Blood Management (PBM) leads to an overall decrease in 
transfusion demand by 39% and results in reduced morbidity, namely 25% reduce in acute renal failure and thrombotic 
events. PBM is an evidence-based multimodal approach based on three main pillars: diagnosis and treatment of anemia, 
minimizing (iatrogenic) blood loss, rationale use of blood units. Its most important components are: Preoperative intravenous 
iron substitution; Intraoperative tranexamic acid; Maintaining physiological conditions: normothermia, pH > 7.2, Calcium > 
1.1 mmol/L; Cell salvage and re-transfusion of processed blood; Single-unit policy (reassessment after each blood unit); 
Rational numbers of diagnostic blood samples; Non-invasive hemoglobin measurement; Correction of coagulation anomalies 
ASAP.  
Testing 
 FDA names 27 antibody tests that no longer meet regulation to be sold 
Reuters: FDA found 27 antibody tests that no longer meet regulation. According to bridged rules announced May 4, vendors 
must apply for emergency FDA authorization for tests within 10 days. The FDA had previously listed 200+ companies that had 
intended to sell the tests, more than half of which were from China.  
 CDC guide for interpreting antibody test results and determining what actions to take 
It lists actions one should take depending on the antibody test results, positive or negative, along with information on 
evaluating and testing for healthcare professionals. 
Drugs, Vaccines, Therapies, Clinical Trials  
 Coronavirus vaccine trials delivered their first results but promise unclear 
Nature: More than 90 vaccines are being developed against SARS-CoV-2 by research teams in companies and universities 
across the world. Researchers are trialing different technologies, some of which haven’t been used in a licensed vaccine 
before. At least six groups have already begun injecting formulations into volunteers in safety trials; others have started 
testing in animals. Nature’s graphical guide explains each vaccine design (https://www.nature.com/articles/d41586-020-
01221-y).  Moderna revealed its COVID-19 vaccine triggered an immune response in people, and protected mice from lung 
infections with the coronavirus SARS-CoV-2. Tests of other fast-tracked vaccines show that they have prevented infections in 
the lungs of monkeys exposed to SARS-CoV-2, but not in some other parts of the body. A vaccine being developed at the 
University of Oxford, UK, that is also in human trials — protected six monkeys from pneumonia, but the animals’ noses 
harbored as much virus as did those of unvaccinated monkeys, researchers reported1 last week in a bioRxiv preprint. A 
Chinese group reported similar caveats about its own vaccine’s early animal tests this month. Despite uncertainties, all three 
teams are pressing ahead with clinical trials  
 Oxford and AstraZeneca COVID-19 vaccine candidate to move to larger human trials 
Oxford University and AstraZeneca are recruiting around 10,000 adults and children in Britain for trials of an experimental 
coronavirus vaccine, a day after receiving U.S. backing worth up to $1.2 billion. Researchers are mainly looking for healthcare 
staff and other public-facing workers to join the trial as in order to get a clear signal on the vaccine’s efficacy. 
 A human monoclonal antibody blocking SARS-CoV-2 infection 
This is the first report of a human monoclonal antibody that neutralizes SARS-CoV-2 (and SARS-CoV) in cell culture. This cross-
neutralizing antibody targets a communal epitope on these viruses and may offer potential for prevention and treatment of 
COVID-19.  
   
 
   
 
 Hydroxychloroquine or chloroquine +/- macrolide does not confer benefit and increases frequency of 
ventricular arrhythmia 
A multinational registry analysis of the use of hydroxychloroquine or chloroquine with or without a macrolide was unable to 
confirm a benefit when used for treatment of COVID-19. Each of these drug regimens was associated with decreased in-
hospital survival and increased frequency of ventricular arrhythmias.  
 Adjuvant corticosteroid therapy for critically ill patients with COVID-19 
The data on 244 patients with COVID-19 who had complete records and were critically ill and treated with antiviral agents 
were enrolled. All patients were given antiviral therapy and 151 patients (62%) were given adjuvant corticosteroid treatment. 
Multivariate analysis adjusted for major mortality-associated variables and propensity score and indicated that corticosteroid 
treatment was independent from overall mortality at 28 days after admission (adjusted OR 1.05) The addition of adjuvant 
corticosteroid therapy was not associated with28-day mortality. However, increased corticosteroid dosage was significantly 
associated with elevated mortality risk after adjustment for administration duration; every 10-mgincrease in dosage was 
associated with an additional 4% mortality risk. 
 A comprehensive review on drug repositioning against COVID19 
Old drugs that may be effective are from different pharmacological categories such as antimalarials, anthelmintic, anti-
protozoal, anti-HIVs, anti-influenza, anti-hepacivirus, antineoplastic, neutralizing antibodies, immunoglobulins, and 
interferons. In vitro, in vivo, or preliminary trials of these drugs in the treatment of COVID-19 have been encouraging, leading 
to new research projects and trials to find the best drug/s. In this review, the authors discuss the possible mechanisms of 
these drugs against COVID-19.  
 Vaccines inducing antibodies targeting SARS-CoV-2 receptor binding domain may be broadly effective 
MedRx preprint: Virus entry into cells depends on the receptor binding domain (RBD) of the SARS-CoV-2 spike (S) protein. 
ELISA assays performed on the plasma of 149 convalescent patients revealed low titers of rare, but recurring RBD-specific 
antibodies in every individual tested. Despite low titers, antibodies to 3 distinct epitopes on RBD neutralized at half-maximal 
inhibitory concentrations (IC50s) as low as single digit ng/mL. Females were found to have lower anti-RBD, anti-S IgG titers 
and overall lower neutralizing activity than males.  
 30 New COVID-19 Trials registered today at clinicaltrials.gov 
Treatment trials:  Clarithromycin, RT-PCR, Inflammasome and platelets, ACT-20, Immunogenic Viral Epitopes, Levilimab, 
Inopulse, Heparin, Marilimumab, Thales Thermography Triage, Immunomodulatory MSC, GCO-002 CACOVID-19. At the time 
of writing, a total of 1565 were active,  92 completed, and 3 posted results. 
Other Science 
 Increased severity and mortality of COVID-19 in patients with liver and kidney diseases 
A meta-analysis of 22 studies including 5595 COVID-19 patients showed that, in patients with COVID-19 and underlying liver 
diseases, 57.33% (43/75) of cases were severe, with 17.65% mortality, while in CKD patients, 83.93% (47/56) of cases were 
severe and 53.33% (8/15) mortality was reported. The prevalence of liver diseases and chronic kidney disease (CKD) in 
COVID-19 patients were 3% (95% CI; 2-3%) and 1% (95% CI; 1-2%). 
 No evidence of vertical transmission in late pregnancy 
A meta-analysis was conducted on 87 SARS-CoV-2 positive pregnant women. 78% suffered from mild or moderate COVID-19, 
99.9%, 86% had cough, and 68% had fever (p = .022 and p < .001). The overall proportions of vertical transmission, still birth, 
and neonatal death were zero, 0.002, and, 0.002, respectively (p = 1, p = .86, and p = .89, respectively). The means of the 
first- and fifth-minute Apgar scores were 8.86 and 9, respectively (p < .001 for both). The authors report no evidence of 
vertical transmission at least in late pregnancy. Although pregnant women are at an immunosuppressive state due to the 
physiological changes during pregnancy, most patients suffered from mild or moderate COVID-19 pneumonia with no 
pregnancy loss. 
 Pathophysiology of SARS-CoV-2: Results from Mount Sinai autopsies 
   
 
   
 
MedRx preprint: Novel findings from autopsies of 67 COVID-19 positive patients include an endothelial phenotype of ACE2 in 
selected organs, which correlates with clotting abnormalities and thrombotic microangiopathy, addressing the prominent 
coagulopathy and neuropsychiatric symptoms. Another original observation is that of macrophage activation syndrome, with 
hemophagocytosis and a hemophagocytic lymphohistiocytosis-like disorder, underlying the microangiopathy and excessive 
cytokine release.  
 Readmission characteristics include COPD, HTN, and lower rates of anticoagulation 
MedRx preprint: Low number of patients return to the hospital after discharge, but of those the most common reason for 
return was respiratory distress. These patients had a shorter initial length of stay, less likely to have been admitted to the 
ICU, a higher proportion of COPD and hypertension, and a trend towards lower rates of in-hospital treatment-dose 
anticoagulation.  
 Low blood sodium associated with increased risk and severity 
MedRx preprint: The authors of this systematic review and meta-analysis report that the mean serum sodium concentration 
in severe/critical patients (137.0) was significantly lower than those in mild and moderate patients (140.8 and 138.7, 
respectively). Changes were not obvious in the serum chlorine and potassium concentrations. The low sodium state may not 
be the consequence of virus infection, but could be a physiological state possibly caused by living habits such as low salt diet 
and during aging process, which may result in ACE2 overexpression, and increase the risk and severity.  
 Simulated sunlight rapidly inactivates SARS-CoV-2 on surfaces 
Simulated sunlight rapidly inactivated SARS-CoV-2 suspended in either simulated saliva or culture media and dried on 
stainless steel coupons. Ninety percent of infectious virus was inactivated every 6.8 minutes in simulated saliva and every 
14.3 minutes in culture media when exposed to simulated sunlight representative of the summer solstice at 40oN latitude at 
sea level on a clear day. Significant inactivation also occurred, albeit at a slower rate, under lower simulated sunlight levels. 
The present study provides the first evidence that sunlight may rapidly inactivate SARS-CoV-2 on surfaces, these data indicate 
that natural sunlight may be effective as a disinfectant for contaminated non-porous materials.  
Contributing team members: Christophe G. Lambert, Shawn Stoicu, Ingrid Hendrix, Lori Sloane, Mari Anixter, 
Anastasiya Nestsiarovich, Praveen Kumar, Nicolas Lauve, Laura Gonzalez Bosc, Melissa Cossé, Jenny Situ, 
Randy Ko, Ariel Hurwitz, Kristine Tollestrup, Douglas J. Perkins.  
Disclaimer: The UNM Global Health COVID-19 Briefing is provided as a public service. Sources include not only 
peer-reviewed literature, but also preliminary research manuscripts that have not been peer reviewed along 
with lay news media reports. The peer-review process often results in manuscript improvement, with 
corrections made for errors and unsubstantiated conclusions being corrected. Furthermore, many headlines 
and summaries in the briefing are written by student volunteers and others who may lack subject matter 
expertise in this rapidly evolving field. As such, the headlines and summaries should not be regarded as 
conclusive. Instead, readers are encouraged to use the briefing to identify areas of interest and then use the 
embedded links to read and critically evaluate the primary sources. 
